Understanding PK/PD

Intensive Care Medicine

Volumn 42, Issue 11, 2016, Pages 1797-1800

  Roberts, Jason A ^a,b   Taccone, Fabio Silvio ^c   Lipman, Jeffrey ^a,b,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c ERASME HOSPITAL   (Belgium)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; COLISTIN; ECHINOCANDIN; GLYCOPEPTIDE; QUINOLONE DERIVATIVE; TRIAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL EFFECTIVENESS; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DOSE; EXTRACORPOREAL OXYGENATION; FLUID BALANCE; FLUID RESUSCITATION; HUMAN; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NEUROTOXICITY; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RENAL CLEARANCE; RENAL REPLACEMENT THERAPY; CRITICAL ILLNESS; DOSE RESPONSE;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACOKINETICS;

EID: 84940704278     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-4032-6     Document Type: Article

References (15)

1. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney B, Ungerer J, Lipman J, Roberts JA (2012) Sub-therapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30–39
2. Blot S, Lipman J, Roberts DM, Roberts JA (2014) The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary? Diagn Microbiol Infect Dis 79:77–84
3. Jamal JA, Economou CJ, Lipman J, Roberts JA (2012) Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 18:460–471
4. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083
5. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498–509
6. Valenza G, Seifert H, Decker-Burgard S, Laeuffer J, Morrissey I, Mutters R (2012) Comparative activity of carbapenem testing (COMPACT) study in Germany. Int J Antimicrob Agents 39:255–258
7. Blot S, Koulenti D, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Roberts JA (2014) Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care 18:R99
8. Roberts JA, Stove V, De Waele JJ, Sipinkoski B, McWhinney B, Ungerer JP, Akova M, Bassetti M, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J (2014) Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. Int J Antimicrob Agents 43:423–430
9. Sinnollareddy M, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, Kaukonen K-M, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Dimopoulos G (2015) Pharmacokinetic variability and exposures of fluconazole, anidulafungin and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (DALI) patients Study. Crit Care 19:33
10. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ (2003) Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42:1411–1423
11. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073–1081
12. Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725–1730
13. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL (2002) Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50:425–428
14. Beumier M, Casu GS, Hites M, Wolff F, Cotton F, Vincent JL, Jacobs F, Taccone FS (2015) Elevated beta-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol 81:497–506
15. Roberts JA, Taccone FS, Udy AA, Jacobs F, Louis J-L, Lipman J (2011) Vancomycin dosing in critically ill patients—robust methods for improved continuous infusion regimens. Antimicrob Agents Chemother 55:2704–2709